Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.

Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Vanderkooi OG, Schryvers A, De Serres G, Alcantara J.

Vaccine. 2012 Jun 8;30(27):4023-7. doi: 10.1016/j.vaccine.2012.04.034. Epub 2012 Apr 23.

PMID:
22537988
3.

Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.

Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N.

Pediatr Infect Dis J. 2012 Oct;31(10):1074-7.

PMID:
22828645
4.

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609.

PMID:
19325450
5.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
6.

The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.

Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.

Int J Infect Dis. 2008 May;12(3):278-88. Epub 2007 Nov 5.

7.

A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.

Díez-Domingo J, Cantarino MV, Torrentí JM, Sansano MI, Rosich AJ, Merino AH, de Miguel AG, González JB, Marcos MD; MenC Study Group.

Pediatr Infect Dis J. 2010 Feb;29(2):148-52. doi: 10.1097/INF.0b013e3181b9a831.

PMID:
19927040
8.

Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.

Al-Mazrou Y, Khalil M, Borrow R, Balmer P, Bramwell J, Lal G, Andrews N, Al-Jeffri M.

Infect Immun. 2005 May;73(5):2932-9.

9.

A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.

Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ.

Pediatr Infect Dis J. 2007 Nov;26(11):1057-9.

PMID:
17984816
10.

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, Sanders EA, Berbers GA, van der Klis FR.

PLoS One. 2010 Aug 13;5(8):e12144. doi: 10.1371/journal.pone.0012144.

11.

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.

de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, Diggle L, John TM, Yu LM, Omar O, Borkowski A, Pollard AJ.

Pediatr Infect Dis J. 2011 Nov;30(11):e203-8. doi: 10.1097/INF.0b013e318224fb14.

PMID:
21673612
12.
13.

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, Akinsola AK, Idoko OT, Diallo F, Adegbola R, Tang Y, Parulekar V, Chadha H, Mabey L, Holme D, Townsend K, Chaumont J, Laforce FM, Kulkarni PS, Marchetti E, Viviani S, Hassan-King M, Preziosi MP.

Clin Vaccine Immunol. 2011 Sep;18(9):1492-6. doi: 10.1128/CVI.05020-11. Epub 2011 Jul 13.

14.

Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.

Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM, Muro Brussi M, Sánchez-Tamayo T, Castro Fernandez J, Cabanillas L, Peddiraju K, Mesaros N, Miller JM.

Pediatr Infect Dis J. 2011 Nov;30(11):e216-24. doi: 10.1097/INF.0b013e3182293a82.

PMID:
21747321
16.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
17.

A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.

Riddell A, Buttery JP, McVernon J, Chantler T, Lane L, Bowen-Morris J, Diggle L, Morris R, Lockhart S, Pollard AJ, Cartwright K, Moxon ER.

Vaccine. 2007 May 10;25(19):3906-12. Epub 2007 Feb 7.

PMID:
17368663
18.

Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.

Stoof SP, van Ravenhorst MB, van Rooijen DM, de Voer RM, van der Klis FR, Boland GJ, Sanders EA, Berbers GA, Teunis PF.

Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00429-16. doi: 10.1128/CVI.00429-16. Print 2017 Feb.

19.

Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.

Tejedor JC, Moro M, Merino JM, Gómez-Campderá JA, García-del-Rio M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Ruiz-Contreras J, Martin-Ancel A, Roca J, Boceta R, García-Corbeira P, Maechler G, Boutriau D; Spanish 102547 Study Group.

Pediatr Infect Dis J. 2008 Jul;27(7):579-88. doi: 10.1097/INF.0b013e31816b4561.

PMID:
18536619
20.

Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.

McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER.

Pediatr Infect Dis J. 2002 Aug;21(8):747-53.

PMID:
12192163

Supplemental Content

Support Center